Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan Capital
Tweet Send to a Friend
Chardan Capital affirms Medicines Company (Nasdaq: MDCO) with a Buy rating and $50 price target after the company and Alnylam ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
